Please assess the completion status of the following clinical trial:

Trial Title: Safety of Cotrimoxazole in HIV- and HAART-exposed Infants

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Both maternal and infant criteria need to be met:~Maternal Inclusion Criteria:~* documented HIV infection~* taking 3-drug highly active antiretroviral therapy at any point during pregnancy (note: can include 2 NRTI+NNRTI, 2NRTI+PI, or 3 NRTI)~* 21 years of age or older, and able and willing to sign informed consent~* Proof of Botswana Citizenship~Maternal Exclusion Criteria:~* involuntary incarceration~Infant Inclusion Criteria:~* younger than 42 days of age~* able to be brought to regular visits at study clinic until at least 6 months postpartum~Infant Exclusion Criteria:~* known pre-existing birth anomalies resulting in a high probability that the baby will not survive to 6 months~* known hypersensitivity to cotrimoxazole

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cotrimoxazole (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).